AbbVie Unusual Options Activity For April 05-July 2024-www.financetom.com

AbbVie Unusual Options Activity For April 05

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

AbbVie Unusual Options Activity For April 05

Apr 5, 2024 1:47 PM

Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie ( ABBV ).

Looking at options history for AbbVie ( ABBV ) we detected 25 trades.

If we consider the specifics of each trade, it is accurate to state that 32% of the investors opened trades with bullish expectations and 68% with bearish.

From the overall spotted trades, 11 are puts, for a total amount of $593,316 and 14, calls, for a total amount of $795,585.

Predicted Price Range

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $125.0 to $195.0 for AbbVie ( ABBV ) over the last 3 months.

Volume & Open Interest Development

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in AbbVie's ( ABBV ) options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to AbbVie's ( ABBV ) substantial trades, within a strike price spectrum from $125.0 to $195.0 over the preceding 30 days.

AbbVie Option Volume And Open Interest Over Last 30 Days

Significant Options Trades Detected:

Symbol	PUT/CALL	Trade Type	Sentiment	Exp. Date	Ask	Bid	Price	Strike Price	Total Trade Price	Open Interest	Volume
ABBV	CALL	TRADE	BEARISH	01/17/25	$5.0	$4.8	$4.8	$195.00	$163.2K	1.2K	341
ABBV	PUT	TRADE	BULLISH	01/17/25	$21.35	$21.0	$21.0	$185.00	$128.1K	32	67
ABBV	CALL	SWEEP	BEARISH	04/26/24	$2.28	$2.12	$2.28	$175.00	$91.2K	279	2.2K
ABBV	CALL	TRADE	BEARISH	05/17/24	$5.4	$5.3	$5.3	$170.00	$90.1K	5.6K	292
ABBV	PUT	TRADE	BEARISH	01/17/25	$2.5	$2.28	$2.5	$130.00	$85.0K	1.7K	340

About AbbVie

AbbVie ( ABBV ) is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

In light of the recent options history for AbbVie ( ABBV ), it's now appropriate to focus on the company itself. We aim to explore its current performance.

Where Is AbbVie Standing Right Now?

Currently trading with a volume of 6,634,397, the ABBV's price is up by 1.25%, now at $170.0.

RSI readings suggest the stock is currently may be approaching oversold.

Anticipated earnings release is in 21 days.

What Analysts Are Saying About AbbVie

In the last month, 2 experts released ratings on this stock with an average target price of $192.5.

An analyst from Barclays persists with their Overweight rating on AbbVie ( ABBV ), maintaining a target price of $195.

An analyst from Guggenheim has decided to maintain their Buy rating on AbbVie ( ABBV ), which currently sits at a price target of $190.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for AbbVie ( ABBV ), Benzinga Pro gives you real-time options trades alerts.

Previous page： Smucker seeks to divest cookie brand Voortman, sources say Next page： Charter to pay $15 million to resolve US probe into network outage rules

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Smucker seeks to divest cookie brand Voortman, sources say

Jul 29, 2024

NEW YORK (Reuters) - J.M. Smucker, known primarily for its jams and jellies, is exploring a sale of Voortman Bakery in a deal that could value the cookie and wafer brand at more than $350 million, according to people familiar with the matter. Smucker, which last year agreed to a $5.6 billion deal for Twinkies maker Hostess Brands, is working...

Charter to pay $15 million to resolve US probe into network outage rules

Jul 29, 2024

WASHINGTON, July 29 (Reuters) - Charter Communications ( CHTR ) will pay a $15 million civil penalty to resolve an investigation into compliance with network and 911 outage notification rules, the Federal Communications Commission said on Monday. The FCC said Charter admitted to violating the agency's rules on notifications to public safety officials and the commission in connection with three...

Smucker seeks to divest cookie brand Voortman, sources say

Jul 29, 2024

NEW YORK, July 29 (Reuters) - J.M. Smucker, known primarily for its jams and jellies, is exploring a sale of Voortman Bakery in a deal that could value the cookie and wafer brand at more than $350 million, according to people familiar with the matter. Smucker, which last year agreed to a $5.6 billion deal for Twinkies maker Hostess Brands,...

Hni Insider Sold Shares Worth $317,599, According to a Recent SEC Filing

Jul 29, 2024

03:47 PM EDT, 07/29/2024 (MT Newswires) -- Steven M Bradford, Senior Vice President, General Counsel, and Secretary, on July 25, 2024, sold 5,976 shares in Hni (HNI) for $317,599. Following the Form 4 filing with the SEC, Bradford has control over a total of 64,169 shares of the company, with 61,642 shares held directly and 2,527 controlled indirectly. SEC Filing:...